



Poly Medicure Ltd.

Works : Plot No. 104-105, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad-121004, INDIA
Phone : +91-129-4287000, 3355070, Fax : +91-129-2307007, 2309102
E-mail : info@polymedicure.com, Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

POLYMED
Medical Devices

Date : 04/09/2015

FORM-A

(Pursuant to Clause 31(a) of the Listing Agreement)

1	Name of the Company	Poly Medicure Limited
2	Annual Financial Statements for the year ended	31 st March, 2015
3	Types of Audit observation	Un-qualified
4	Frequency of observation	Not Applicable

For Poly Medicure Limited

(HIMANSHU BAID)
Managing Director

For Poly Medicure Limited

(J.K. OSWAL)
Vice President(Finance) & CFO

For Poly Medicure Limited

(SOHAN RAJ MOHNOT)
Chairman of Audit Committee

For M/s. DOOGAR & ASSOCIATES
Chartered Accountants

(M.S. AGARWAL)
Partner
Membership No. 86580



innovation

safety

quality

Poly Medicure Limited
Annual Report 2014-15



Corporate Information

Board of Directors

Chairman

Devendra Raj Mehta

Non-Executive Independent Directors

Sohan Raj Mohnot

Prakash Chand Surana

Yeshwant Singh Choudhary

Shailendra Raj Mehta

Non-Executive Directors

Jugal Kishore Baid

Mukulika Baid (w.e.f. 30th July 2014)

Managing Director

Himanshu Baid

Executive Director

Rishi Baid

Company Secretary

Avinash Chandra

Key Executives

Vishal Baid, President (Corporate Sales & Marketing)

V. K. Khera, Sr. V P (Export)

J. K. Oswal, V P (Finance) and CFO

Hemant Bhalla, V P (Sales & Marketing)

Bankers

State Bank of India

Citibank N.A.

Auditors

M/s Doogar & Associates

New Delhi

Cost Auditors

M/s Jai Prakash & Co.

Faridabad

Registrar and Transfer Agents

MAS Services Limited,

T-34, 2nd Floor,

Okhla Industrial Area, Phase-II,

New Delhi-110020

Tel:+ 91(011)-26387281/82

Fax No. 011- 26387384

E-mail: mas_serv@yahoo.com

Website: www.masserve.com

Registered Office

232B, 3rd Floor, Okhla Industrial Estate,
Phase III

New Delhi – 110020 (India)

Tel No.: 91 11 - 26321838, 81, 89, 93

Fax No.: 91 11 – 26321839, 94

Email: investorcare@polymedicure.com

Website: www.polymedicure.com


CIN: L40300DL1995PLC066923

Inside this Report:


Company Overview	Key Performance Indicator	1
	Manufacturing Facilities	2
	Exhibition & CSR Activities	3
	Product Range	4
	Financial Highlights	5
	Letters to Shareholders	6
Statutory Reports	Notice of Annual General Meeting	9
	Directors' Report	17
	Annexures of Directors' Report	21
	Report on Corporate Governance	53
Financial Statements	Independent Auditors' Report on Financial Statements	66
	Balance Sheet	69
	Statement of Profit and Loss	70
	Cash Flow Statement	71
	Significant Accounting Policies	72
	Notes on Financial Statements	76
	Independent Auditors' Report on Consolidated Financial Statements	97
	Consolidated Balance Sheet	101
	Consolidated Statement of Profit and Loss	102
	Consolidated Cash Flow Statement	103
	Significant Accounting Policies on Consolidated Accounts	104
	Notes on Consolidated Accounts Financial Statements	108
	Statement of Salient features of the Financial Statements of Subsidiaries and Associate	129

Key Performance Indicators:


Revenue (₹ Crore)




EPS (₹) Adjusted with bonus




PAT (₹ Crore)




Gross Fixed Assets (₹ Crore)




EBITDA (₹ Crore)




Dividend (in %), Adjusted with bonus



Net Worth (₹ Crore)



Market Capitalisation (₹ Crore)



Manufacturing Facilities



Unit I at Faridabad, Haryana



Unit II at Faridabad, Haryana



Unit III at Haridwar, Uttarakhand



Unit IV at SEZ Jaipur, Rajasthan (New Facility)



100% Subsidiary in China


Automatic production Lines



CMEs Conducted in various hospitals



Participation in various exhibitions



Corporate Social Responsibility



Product Range:

Infusion Therapy

Safety I.V. Cannula
I.V. Cannula
Quick Flashback I.V. Cannula
Needle Free Connectors
Three Way Stop Cocks
I.V. Infusion Sets
I.V. Flow Regulators
Extension Lines
T-type Extension Set
CVP Manometer
Safety Winged Infusion Set
Safety Scalp vein Sets

Central Venous Access Catheters

Central Venous Catheters (Single / Double / Triple Lumen)

Anaesthesia

Oxygen Catheters
Suction Catheters
Oxygen mask with Reservoir
Guedel Airways
Respiratory Exerciser
Nasal Oxygen Tubes
Oxygen Masks
Aerosol Therapy masks
Fixed Concentration Masks
Endotracheal Tubes
Tracheostomy Tubes
Spinal Needles
Catheter Mount

Urology

Urine Collection Bags
Measured Volume Urine Meter
Urine Drainage Catheters
TUR Sets
Foley Balloon Catheters
Irrigation Sets

Gastroenterology

Ryle's Tubes
Levin's Tubes
Infant Feeding Tubes
Mucus Extractors
Umbilical Catheter
Feeding Bag
T Tube

Blood Management & Blood Collection Systems

Blood Administration Sets
Blood Bag Systems
Transfusion Pump Set
Blood Bag with Safety Device & Sampling Bag
CPD-SAGM-TOTM Bag System
Top & Bottom Extraction Bag System
ACD Bag
Blood Collection Tubes and Needles
Safety Blood Collection Sets

Surgery and Wound Drainage

Redon Drains
Thoracic Drainage Catheters
Abdominal Drainage Sets
Under Water Seal Drainage Systems
Yankauer Suction Sets
Yankauer Suction Handle
Under Water Seal Drainage Bottle
Colostomy Bag
Closed Wound Suction Units
High Pressure Vacuum Bottles with Extension Tube

Dialysis

Fistula Needles
Safety Fistula Needles
Blood Lines
Haemodialysis Catheter
Peritoneal Dialysis Transfusion Set

Others

Insulin Syringes
Umbilical Cord Clamps
Sputum Collector
Dry Brush

Financial Highlights

	2014-15	2013-14	2012-13	2011-12	(₹ in lacs) 2010-11
Revenue From Operations (Net)	37,368.83	31,233.32	25,223.79	20,891.86	16,966.75
Total Revenue	38,190.97	31,339.52	25,260.55	20,953.81	17,006.06
Earnings Before Depreciation, Finance Cost and Tax Expenses (EBDIT)	9,085.46	7,369.56	5,152.02	4,577.28	3,666.20
Depreciation and Amortisation	1,808.99	1,351.06	1,182.06	995.52	858.79
Exceptional Items	(1,957.80)	(991.46)	-	-	-
Profit For the Year	6,101.72	4,303.21	2,402.92	1,925.96	2,169.02
Equity Dividend %*	50%	40%	40%	30%	30%
Dividend Payout	1,102.84	881.33	440.50	330.38	330.38
Equity Share Capital	2,205.67	2,203.32	1,101.25	1,101.25	1,101.25
Reserves and Surplus	16,991.29	12,226.21	10,002.73	8,188.32	6,676.50
Net Worth	19,196.96	14,429.95	11,103.98	9,289.57	7,777.75
Gross Fixed Assets	26,194.87	21,335.69	15,719.38	13,539.00	11,274.13
Net Fixed Assets	17,046.39	14,008.95	9,715.95	8,673.33	7,250.83
Total Assets	35,445.67	28,248.21	21,193.00	17,976.48	15,195.57
Market Capitalisation	2,22,684.65	99,656.00	49,556.00	27,928.00	30,615.00
Number of Employees	1586	1478	1329	1210	1027

Key Indicators

	2014-15	2013-14	2012-13	2011-12	2010-11
Earnings Per Share - (₹)*	13.83	9.77	5.45	4.37	4.92
Turnover Per Share - (₹)*	84.71	70.88	57.26	47.43	38.52
Book Value Per Share - (₹)*	43.52	32.75	25.21	21.09	17.66
Debt : Equity Ratio	0.40:1	0.46:1	0.44:1	0.49:1	0.53:1
EBDIT/ Net Turnover %	24.31%	23.60%	20.43%	21.91%	21.61%
Net Profit Margin %	16.33%	13.78%	9.53%	9.22%	12.78%
RONW %	31.78%	29.82%	21.64%	20.73%	27.89%
ROCE %	22.78%	20.37%	15.04%	13.87%	18.22%

*Adjusted for issue of Bonus Share in FY 2013-14 in the ratio of 1:1

*Adjusted for sub-division of nominal face value of one equity share of ₹ 10 each into two equity share of ₹ 5 each in FY 2014-15.

LETTER FROM THE CHAIRMAN



Dear Shareholders,

This reporting year represents a very special occasion for us. First, we are completing another successful financial year with a good growth record. Second, we are launching our ambitious five year plan, "Vision 2020". To crown this, we complete two decades of our eventful existence. In 1995 twenty years ago we started this company, Poly Medicure Limited, inspired by the vision of providing quality products of healthcare to all and began this exciting and may rightfully call this glorious journey.

I am pleased to report that your Company performed very well in 2014-15. The Company made commendable progress in the medical sector, especially the vital devices segment. The Company continues to show marked improvement on all financial parameters.

Your Company's total revenue increased from ₹ 322.25 crore to ₹ 390.35 crore during the year, registering a healthy growth of 21.13%. Likewise, EBITDA expanded to ₹ 92.24 crore as against ₹ 75.29 crore during the preceding year, which translates into an increase of 22.51%. The improvement in profitability has been possible due to continuous introduction of new product innovations which

helped also the existing products to focus on growth. What is reassuring is that the Company will be launching a range of new products both in domestic and overseas markets.

In keeping with the Company's vision of creating sustainable value, the focus on safety, Corporate Social Responsibility (CSR), Sustainability and Human Resources continues to be of great importance. I am happy to report that the Company's CSR activities touched many lives last year. Poly Medicure serves the society, in the domains of education, healthcare, hunger and sanitation. Our relief and rehabilitation efforts in Kashmir and other areas affected by natural calamities earned significant respect.

In brief, Poly Medicure has continued to make good progress in building a sustainable business model that delivers superior value to its shareholders. The long term drivers for our Company remain in place and I am confident that this, together with our robust strategy reinforced by advanced technology, should support the continuing growth of the Company over the years ahead.

Let me end with my thanks to our customers, dealers, vendors and employees, who have always done their utmost for the Company, and my special thanks to you for your support.

D. R. Mehta
Chairman

New Delhi
31st July 2015